No profile data available.
Adma Biologics, Inc. (ADMA) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Ramsey, United States, with about 640 full-time employees.
It reported revenue of $510.17 million for fiscal year 2025, up 19.6% from fiscal year 2024, and net income of $146.93 million. Its largest business segment, ADMA Biomanufacturing, brought in 97% of segment revenue in fiscal year 2025; United States was the largest region with 99%. Its market capitalization was $2.32 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Adma Biologics reported $510.17 million in revenue for fiscal year 2025, up 19.6% from $426.45 million in fiscal year 2024.
ADMA Biomanufacturing, with $493.00 million or 97% of segment revenue in fiscal year 2025. Next: Plasma Collection Centers (3%).
United States: 99% of revenue by region in fiscal year 2025, followed by International (1%).
$2.32 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Prestige Consumer Healthcare Inc. (PBH), Beam Therapeutics Inc. (BEAM), Terns Pharmaceuticals, Inc. (TERN), Nurix Therapeutics, Inc. (NRIX).